Medical Bulletin Board

Read Article

Megalabs Usa Enters North American Market. Plans Expansion of Prunelax™ Gummies Formulation

Megalabs USA, a subsidiary of Megalabs International Inc., has opened offices in Miami, FL and will be headed by CEO Mr. Fabian Rivero. Before taking the CEO position, Mr. Rivero was the Chief Legal Officer & Member of the Board of Directors of Megalabs (a multinational Pharmaceutical & Biotechnology Group) and continues to be an active member of the company’s Executive Committee. Megalabs USA manufactures (through its affiliates), markets, and distributes overthe-counter products that are formulated with plant extracts, known for their medicinal attributes, and nutraceuticals, vitamins, and minerals to produce highly effective products in various wellness categories. The company’s mission is to develop and market effective over-the-counter medicines and nutraceuticals, preferably of natural origin, that improve the health and quality of our customers’ lives. Among other products, Megalabs USA manufactures and distributes Prunelax, a leader in natural and effective solutions to maintain bowel regularity, and the newly announced and launched Prunelax Gummies, a new option for the brand’s popular lineup of laxative supplements. Prunelax is widely distributed throughout the Americas through multiple retail channels including drug, food, mass, and e-commerce.

CEO Fabian Rivero explained the new product was designed with consumers in mind, adding that, “in a space that sees an abundance of pills, we’re proud to offer a wide variety of Prunelax products ranging from traditional tablets to teas, liquids, and jams.” And also highlights that, “with our new Prunelax Gummies, we expand our line again with a tasty, chewable option for the whole family.” Made from Senna leaves extract and Prune fruit extract that relieves occasional constipation and helps maintain bowel regularity, Prunelax products deliver overnight natural relief. Prunelax Gummies feature natural flavors, colorants, and natural active ingredients including Senna and prune fruit extracts, which work in as little as eight hours. Prunelax Gummies are a vegan and gluten-free supplement for occasional constipation for ages four to adult {always consult your healthcare professional for personal health guidance}. Prunelax Gummies are sold at major pharmacy and retail chains such as Walgreens, CVS, and Walmart. In addition to gummies, Prunelax is also available as tablets, liquids, jam, and tea and is one of the only products on the market with Extra Strength dosing options.

About Megalabs USA

Megalabs USA is a subsidiary of Megalabs, an international pharmaceutical company that manufactures, markets and distributes pharmaceutical products. It distributes over-thecounter products formulated with plant extracts known for their medicinal attributes, combining them with nutraceuticals, vitamins, and minerals to produce highly effective products for various wellness categories. Our mission is to develop and market effective, among others, over-the-counter medicines and nutraceuticals, preferably of natural origin, that improve the health and quality of our customers’ lives. Company products are readily available in all markets in the Americas through subsidiaries and distributors, highly committed to our brands, and active in multiple retail channels, including drug, food, mass, and e-commerce. Our vision has led us to build a successful multinational company with leading quality and effective products in the essential categories of over-thecounter medicines and nutraceuticals. And we have achieved this while complying with the standards and procedures related to drug manufacturing processes to ensure the efficacy and safety of our products. Megalabs USA has developed and provided effective, over-the-counter products and supplements that use natural ingredients to improve people’s health and quality of life. The company’s product, Prunelax, is one of the top natural solutions for digestive disorders in Latin America and is highly popular across North America.

For more information on Megalabs USA, please visit:


Ambu will extend market leadership in pulmonology by entering the bronchoscopy suite segment following U.S. and European market clearances.

COLUMBIA, MD – Ambu Inc. announces that Ambu® aScope™ 5 Broncho, a family of singleuse, sterile bronchoscopes, has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA).

Ambu announced European regulatory clearance in May 2022 and will now proceed with commercialization of the aScope 5 Broncho and the full high definition Ambu® aBox™ 2 processing unit in Europe as well as in the USA.


With the aScope 5 Broncho, Ambu now leads the entry of single-use endoscopes in the bronchoscopy suite, a market segment known for its considerably complex medical procedures that require scopes of high-performance image quality and handling. To enter this market, the aScope 5 Broncho family has advanced imaging and design features, including a new high-resolution camera chip, which, in combination with the aBox 2, delivers superior image quality.

“With the aScope 5 Broncho system, I am getting a complete package with all the things that I need for it to be my workhorse scope in the bronchoscopy suite. The way I see where the field is going, I think this is a bronchoscope of the future,” said Dr. Ashutosh Sachdeval, Director of Interventional Pulmonology Program at University of Maryland Medical Center in the Division of Pulmonary and Critical Care, and Assistant Professor of Medicine at the University of Maryland School of Medicine. For healthcare professionals and patients alike in the bronchoscopy suite, Ambu’s fifthgeneration bronchoscope offers sterility as well as a consistently high performance, placing patient safety at the heart of every procedure. Furthermore, the advanced technology, portability, and costeffectiveness of Ambu’s solution makes it an attractive choice for health care providers who need to perform bronchoscopies — not only in the bronchoscopy suite, but across a wide range of care settings, such as operating rooms, intensive care units, and emergency rooms.


The launch of the aScope 5 Broncho family follows Ambu’s ambition of establishing the most comprehensive single-use visualization portfolio within pulmonology.

“We introduced the world’s first flexible singleuse bronchoscope 13 years ago, breaking new ground in intensive care units and operating rooms worldwide. However, until now, the advanced needs in the bronchoscopy suite were never met by single-use scopes. Now, we have created a singleuse portfolio that meets these needs — one that is on par with reusable bronchoscopes, in some areas even superior,” said Bassel Rifai, Chief Marketing Officer at Ambu.

1. Dr. Sachdeva is a paid consultant of Ambu A/S. He has not been compensated for his quote in this press release.

About Ambu

Ambu has brought solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our singleuse endoscopy, anesthesia and patient monitoring solutions. We continuously look ahead with a commitment to deliver innovative quality products that have a positive impact on patient care and the work of healthcare professionals. Headquartered near Copenhagen in Denmark, Ambu employs approximately 5,000 people in Europe, North America and Asia-Pacific.

For more information, please or

Download Tables, Images & References